Research Square
December 22, 2025
Negar Fani, Alexa Kondas, Vishwadeep Ahluwalia et al.
preprint
Vibration-based therapies are understudied but promising methods for alleviating psychiatric symptoms, particularly when paired with behavioral practices. The potential neuroplastic changes associated with a novel neurostimulation method, sternal vibration, and associations with clinical change remain unknown. We examined effects of sternal vibration paired with mindfulness meditation on change...
Preprints.org
December 19, 2025
Elena Koning, Susan Gamberg, Aaron Keshen
preprint
Eating disorders (ED) remain challenging to treat, with high dropout and low remission rates in cognitive-behavioral therapy for EDs (CBT-ED). Psilocybin treatment (PT) demonstrates therapeutic potential to enhance CBT-ED by exerting several neurobiological, psychological, and experiential effects (e.g., antidepressant, neuroplasticity, emotional openness) that are hypothesized to increase...
Creative Science
December 19, 2025
Qinqing Chen, Peiyuan Chen, Tao Wei et al.
Psilocybin, a naturally occurring tryptamine alkaloid found in over 200 species of fungi, has emerged as a focal point in the modern revival of psychedelic science. Once relegated to the margins of psychopharmacology due to its association with counterculture and strict legal restrictions, psilocybin is now undergoing a scientific renaissance. This transformation is driven by its unique...
Journal of Affective Disorders
December 17, 2025
Faheem Ahmed Khan, Nuruliarizki Shinta Pandupuspitasari, Tewin Tencomnao et al.
2 citations
Psilocybin, a naturally occurring hallucinogenic substance present in certain mushrooms, has drawn growing attention as a therapeutic breakthrough for several mental and psychiatric conditions. Psilocybin originated in spiritual and cultural traditions and has become the focus of extensive scientific research. This meta-analysis and systematic review aggregate results from the literature to...
The MIT Press eBooks
December 16, 2025
Idan Segev
Why brain: I was attracted to study the brain because, as a child, I saw around me a lot of emotional suffering.I then thought to myself that, if I could understand the source of such suffering in the brain, I could provide a direct solution to suffering by developing some antisuffering pill or a focal electrical stimulation to relieve the source of pain.Already, during my army service, I...
Psychedelic Medicine
December 16, 2025
Sophie Woodruff, Meghan Hibicke, Charles D. Nichols
Introduction:Psilocybin, a classical psychedelic, has shown to produce persistent antidepressant effects, including in patients with treatment-resistant depression. In clinical practice, it is common to coprescribe benzodiazepines (BZDs) alongside antidepressants. However, our preliminary study indicated that preadministration of lorazepam diminished the antidepressant-like efficacy and...
ACS Medicinal Chemistry Letters
December 16, 2025
Anna C. Renner, Robert B. Kargbo
New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches...
Neuroscience & Biobehavioral Reviews
December 16, 2025
Rivka Vollebregt, A. J. Storm, Paul J. Lucassen et al.
3 citations
Classical psychedelics, like lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and psilocybin, can alter perception, emotion, and cognition, and have shown promise as 're-purposed' treatments for some psychiatric disorders. Recent trials have, e.g., demonstrated rapid and sustained symptom relief in treatment-resistant depression. While promising as a treatment, the...
Current Pain and Headache Reports
December 15, 2025
Alan D. Kaye, Madison C Wolf, Sarah I Dufour et al.
2 citations
Chronic pain and opioid use disorder (OUD) are highly prevalent and frequently co-occurring conditions that pose complex treatment challenges. While opioids are effective for pain management, prolonged use significantly enhances risk of developing substance dependence. Conversely, addiction-focused therapies often fail to relieve persistent somatic pain. Ketamine, an N-methyl-D-aspartate (NMDA)...
Therapeutic Advances in Psychopharmacology
December 11, 2025
Casimiro Cabrera Abreu, Aleksandar Biorac, Ross J. Baldessarini et al.
Ketamine’s development in psychiatry exemplifies the evolution of psychopharmacology over six decades. Originally introduced as a dissociative anesthetic and psychotomimetic probe, ketamine has been repositioned as a rapidly acting antidepressant, particularly for treatment-resistant depression (TRD). This narrative review draws on historical sources, clinical trials, regulatory documents, and...